MedTrace Logo

Analysis of Plasma for Diagnosis and Follow-up of Neurofibromatosis Type 1

NCT02680431 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2016-02-11

No results posted yet for this study

Summary

The purpose of this study is to find blood plasma based biomarkers of disease progression in neurofibromatosis type 1 (NF1). NF1 is associated with the development of benign cutaneous tumors as well as a variety of malignancies. Analysis of plasma DNA and chemical composition may provide tools for diagnosis and follow-up of NF1. The hypothesis of the study is that NF1-associated tumor burden and malignant transformation of tumors can be detected in plasma. To test this hypothesis, Finnish patients with NF1 are recruited and blood sample is taken. Blood plasma is separated and analyzed chemically. DNA is then also extracted and quantified.

Conditions

  • Neurofibromatosis 1

Interventions

OTHER

Blood sample

10 mL venous blood sample for analysis of plasma

Sponsors & Collaborators

  • Juha Peltonen

    lead OTHER_GOV

Principal Investigators

  • Juha Peltonen, Professor · University of Turku

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2020-12-31
Completion
2020-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02680431 on ClinicalTrials.gov